Neueste Versuche

EudraCT Number: 2017-003083-13

Sponsor Protocol Number: 250-202

Start Date:

Sponsor Name: Allievex Corporation

Full Title: A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Safety and Efficacy of Intracerebroventricular AX 250 in Patients with Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo ...

Medical condition: Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B, MPS IIIB)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	10010331 - Congenital, familial and genetic disorders	10056890	Mucopolysaccharidosis III	PT
	20.0	10010331 - Congenital, familial and genetic disorders	10056918	Sanfilippo's syndrome	LLT

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: DE (Ongoing) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2020-004805-30

Sponsor Protocol Number: CLN-PXT3003-06

Start Date:

Sponsor Name: Pharnext SCA

Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A)

Medical condition: Charcot Marie Tooth Type 1A

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004850	10008414	Charcot-Marie-Tooth disease	LLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) BE (Ongoing) NL (Prematurely Ended) DK (Ongoing) ES (Ongoing) IT (Ongoing) FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2018-002611-99

Sponsor Protocol Number: 20090

Start Date:

Sponsor Name: Bayer AG

Full Title: Open-label, randomized, two–arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy ...

Medical condition: Retinopathy of prematurity

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	10015919 - Eye disorders	10038933	Retinopathy of prematurity	PT

Population Age: Preterm newborn infants, Under 18

Gender: Male, Female

Trial protocol: CZ (Completed) SE (Completed) NL (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) SK (Completed) AT (Completed) BG (Completed) PL (Completed) ES (Completed) HU (Completed) LT (Completed) EE (Completed) LV (Completed) GR (Completed) IT (Completed) RO (Completed)

Trial results: View results

EudraCT Number: 2020-001240-25

Sponsor Protocol Number: MOURO48

Start Date:

Sponsor Name: Radboudumc

Full Title: Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer

Medical condition: (metastatic) castration-resistant prostate cancer

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2012-005496-14

Sponsor Protocol Number: MRZ60201_3072_1

Start Date:

Sponsor Name: Merz Pharmaceuticals GmbH

Full Title: Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of upper limb spasticity alone or comb...

Medical condition: Upper limb spasticity or combined upper and lower limb spasticity in children and adolescents (age 2 - 17 years) with cerebral palsy

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004852	10058977	Spastic paresis	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: PL (Completed) Outside EU/EEA

Trial results: View results

EudraCT Number: 2005-003093-21

Sponsor Protocol Number: 20091977

Start Date:

Sponsor Name: Medical Department I

Full Title: Influence of combined therapy of niacin and statins on stem cell mobilization and inflammatory parameters in patients suffering from coronary artery disease – randomized clinical study -

Medical condition: Have stable coronary artery disease (i.e. no acute event like myocardial infarction or PTCA less then 3 months ago)

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2007-002223-32

Sponsor Protocol Number: E2007-0507

Start Date:

Sponsor Name: Charité Universitaetsmedizin

Full Title: A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.

Medical condition: Cardiac surgical patients in whom the use of cardiopulmonary bypass is planned and having at least one ore more of the following risk factors for post-operative acute kidney injury • Age ≥ 70 years...

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) IE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2014-001740-38

Sponsor Protocol Number: P130910

Start Date:

Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

Full Title:

Medical condition:

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	100000004851	10019515	Hemolytic uremic syndrome	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-004708-32

Sponsor Protocol Number: 232SM302

Start Date:

Sponsor Name: Biogen Idec Research Limited

Full Title: A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen

Medical condition: Muscular Atrophy, Spinal

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	10010331 - Congenital, familial and genetic disorders	10041582	Spinal muscular atrophy	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: EE (Completed) ES (Ongoing) HU (Ongoing) DE (Ongoing) PL (Completed) IT (Ongoing) NL (Ongoing) FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2014-003346-27

Sponsor Protocol Number: ATYR1940-C-003

Start Date:

Sponsor Name: ATYR PHARMA, INC.

Full Title: An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Fa...

Medical condition: Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10064087	Facioscapulohumeral muscular dystrophy	PT

Population Age: Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: View results

Neueste Versuche

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen